Goldman Sachs’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-100,000
| Closed | -$1.95M | – | 5585 |
|
|
2018
Q4 | $1.95M | Hold |
100,000
| – | – | ﹤0.01% | 3546 |
|
|
2018
Q3 | $2.66M | Buy |
+100,000
| New | +$3.26M | ﹤0.01% | 3413 |
|
|
2018
Q2 | – | Sell |
-61,200
| Closed | -$2M | – | 6176 |
|
|
2018
Q1 | $2M | Buy |
61,200
+30,200
| +97% | +$1.33M | ﹤0.01% | 3602 |
|
|
2017
Q4 | $1.51M | Sell |
31,000
-2,800
| -8% | -$142K | ﹤0.01% | 4006 |
|
|
2017
Q3 | $1.83M | Buy |
+33,800
| New | +$1.98M | ﹤0.01% | 4081 |
|
|
2017
Q2 | – | Sell |
-70,000
| Closed | -$2.74M | – | 7080 |
|
|
2017
Q1 | $2.74M | Buy |
+70,000
| New | +$2.23M | ﹤0.01% | 3445 |
|
|
2016
Q2 | – | Sell |
-250,000
| Closed | -$5.1M | – | 7366 |
|
|
2016
Q1 | $5.1M | Buy |
+250,000
| New | +$7.93M | ﹤0.01% | 2709 |
|
|
2015
Q4 | – | Sell |
-23,800
| Closed | -$1.01M | – | 7465 |
|
|
2015
Q3 | $1.01M | Buy |
+23,800
| New | +$1.15M | ﹤0.01% | 4465 |
|
Goldman Sachs's PTLA Position: Q3 2020 in Review
Goldman Sachs sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 3,590,091 shares — an estimated $64.6M sold.
Goldman Sachs first reported a position in PTLA in Q2 2013 and held it in 28 quarters. The position peaked at $64.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Goldman Sachs reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Goldman Sachs sold 3,590,091 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $64.6M.
- Goldman Sachs first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
- Goldman Sachs's Portola Pharmaceuticals, Inc. position peaked at $64.6M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Goldman Sachs's 13F filing for Q3 2020, filed 13 Nov 2020.